Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2022-12-19 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Imfinzi + Imjudo recommended for approvals in EU
Regulatory Filings Classification · 98% confidence The document is a press release from AstraZeneca dated December 19, 2022, announcing that the CHMP (Committee for Medicinal Products for Human Use) of the EMA has recommended marketing authorisation for their drugs Imfinzi and Imjudo for advanced liver and lung cancers. This type of announcement, detailing clinical trial results (HIMALAYA and POSEIDON) and regulatory milestones (CHMP recommendation), is characteristic of an Earnings Release (ER) or a general press release regarding significant corporate/product news. Since it focuses on the initial announcement of positive results leading to regulatory action, and is not a full financial report (10-K, IR) or a transcript (CT), the most appropriate classification is Earnings Release (ER), as these often include major product/regulatory updates alongside or instead of quarterly financials. Given the context of a major drug approval update, ER is the best fit among the options provided for a significant, non-financial-statement announcement.
2022-12-19 English
Update on Imfinzi PEARL trial
Regulatory Filings Classification · 98% confidence The document is identified by the 'RNS Number' header and contains a date (19 December 2022) and a headline about a clinical trial update ('Update on PEARL Phase III trial of Imfinzi monotherapy'). The content details the results of a Phase III trial, including quotes from an Executive VP and notes on the disease context and the drug. This structure is typical of a regulatory news service announcement, specifically one reporting material clinical trial outcomes. Since it is a specific announcement of clinical/research results rather than a full financial report (10-K, IR) or a general management change (MANG), it fits best under the general regulatory announcement category, RNS, as it is disseminated via the RNS service and reports on a material event.
2022-12-19 English
Forxiga CHMP opinion for symptomatic chronic HF
Regulatory Filings Classification · 98% confidence The document is a formal announcement dated December 19, 2022, originating from AstraZeneca PLC, identified by the 'RNS Number : 0759K' and the concluding section mentioning RNS, the London Stock Exchange, and the Financial Conduct Authority. The content details a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the EU approval recommendation for the drug Forxiga for a new indication. This type of announcement, which disseminates material, time-sensitive information to the market via an official regulatory news service (RNS), fits the definition of a general regulatory announcement that doesn't fit a more specific category like 10-K, ER, or DIV. Therefore, it is best classified as a Regulatory Filing (RNS). The document length is substantial (13,732 chars), but its primary function is the dissemination of a regulatory update via the RNS system.
2022-12-19 English
UPDATE ON US REVIEW OF LYNPARZA PROPEL SNDA
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides an update on the US regulatory review of Lynparza PROpel sNDA, including details about the FDA's extension of the review period and clinical trial information. The document does not contain comprehensive financial statements or detailed financial analysis typical of annual or interim reports. It is a regulatory update on a drug approval process rather than a financial report or earnings release. Form 6-K filings are typically classified as Regulatory Filings (RNS) because they provide miscellaneous regulatory information from foreign issuers that do not fit into other specific categories. The document length (13,858 characters) is substantial but the content is focused on regulatory and clinical trial updates, not financial results or management discussion. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2022-12-15 English
Update on US review of Lynparza PROpel sNDA
Legal Proceedings Report Classification · 99% confidence The document is identified by the header 'RNS Number' and contains a date stamp (15 December 2022) typical of regulatory news service announcements. The content discusses an update regarding the US FDA's extension of the PDUFA date for a supplementary new drug application (sNDA) for Lynparza. This is a specific, time-sensitive announcement related to regulatory progress for a pharmaceutical product, not a comprehensive financial report (like 10-K or IR) or a general earnings release (ER). Since it is a formal announcement distributed via RNS and concerns regulatory/clinical updates, it fits best under the general 'Regulatory Filings' category, as there is no specific code for 'Regulatory Update on Drug Approval Status'. Given the source (RNS Number) and the nature of the content (an update on regulatory review), RNS is the most appropriate classification.
2022-12-15 English
CAPIVASERTIB PFS IN HR-POSITIVE BREAST CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed clinical trial results (CAPItello-291 Phase III trial) for the drug capivasertib in HR-positive breast cancer, including statistical data, safety profile, and background information on the drug and disease. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about clinical trial results and drug development progress. Form 6-K filings are typically used by foreign issuers to report material information to the SEC and are classified under Regulatory Filings (RNS) in this taxonomy. The document length is substantial (15,000 characters), and it contains substantive content rather than just an announcement or certification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-12-08 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.